Pharmacokinetic Study to Evaluate Double-Dose Levonorgestrel Emergency Contraception in Combination With Efavirenz-Based Antiretroviral Therapy or Rifampicin-Containing Anti-Tuberculosis Therapy

  • STATUS
    Not Recruiting
  • participants needed
    116
  • sponsor
    AIDS Clinical Trials Group
Updated on 20 June 2021
Investigator
Pamela Poethke, R.N.
Primary Contact
The Miriam Hosp. ACTG CRS (2951) (2.3 mi away) Contact
+4 other location
platelet count
body mass index
HIV Infection
antiretroviral agents
antiretroviral therapy
tuberculosis
hiv test
efavirenz
neutrophil count
rifampin
antibody test
hiv-1 infection
hiv-1 rna measurement
hiv-1 antigen
ethambutol

Summary

The purpose of this pharmacokinetic (PK) study is to evaluate if a double dose (3 mg) of levonorgestrel (LNG) emergency contraception (EC) overcomes known drug-drug interactions (DDIs) with efavirenz (EFV)-based antiretroviral therapy (ART) or rifampicin (RIF)-containing tuberculosis (TB) therapy. The safety of double-dose (3.0 mg) LNG EC versus standard-dose (1.5 mg) will also be compared.

Description

This pharmacokinetic (PK) study will evaluate if a double dose (3.0 mg) of levonorgestrel (LNG) emergency contraception (EC) overcomes known drug-drug interactions (DDIs) with efavirenz (EFV)-based antiretroviral therapy (ART) or rifampicin (RIF)-containing tuberculosis (TB) therapy. The safety of double-dose (3.0 mg) LNG EC versus standard-dose (1.5 mg) will also be compared.

Participants will be volunteers who do not currently require EC for contraception. This study will enroll women who are 16 years of age or older. Group assignment will be determined by infection status (HIV or TB; participants cannot be coinfected), and, for those who are living with HIV, by ART regimen at enrollment. Women living with HIV who are taking EFV-based ART will be randomized to receive a standard dose LNG EC (Group A) or a double dose of LNG EC (Group B). Women taking dolutegravir (DTG)-based ART will be assigned to a standard dose of LNG EC (Group C). Women who are HIV-negative and in the continuation phase of active TB treatment taking RIF and isoniazid (INH) will be assigned to a double dose of LNG EC (Group D).

At study entry, participants in Groups A and C will receive a standard single dose of LNG EC. Participants in Groups B and D will receive a double dose of LNG EC. Intensive PK monitoring will be conducted pre-dose, and after the LNG EC dose. Women are expected to be at the clinical site while the initial 8 hour PK samples are collected and may return for the 24 and 48 hour samples.

All participants will complete self-report questionnaires to assess adherence to TB therapy and ART, menstrual history and patterns after LNG EC administration, and to collect adverse effects commonly reported with LNG EC (i.e., irregular bleeding patterns). Adherence to ART and RIF will be assessed by collecting hair samples and single plasma concentrations at entry. All participants will be followed for 4 weeks.

Details
Condition Tuberculosis, HIV infection
Treatment Levonorgestrel Emergency Contraception (LNG EC)
Clinical Study IdentifierNCT03819114
SponsorAIDS Clinical Trials Group
Last Modified on20 June 2021

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note